Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB25FDK70
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,275
Award facts
- Contract value 100% obligated
- $98,274.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $98,274.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 ml vials. This firm fixed-price delivery order, issued on July 23, 2025, is expected to reach completion by August 13, 2025, with performance occurring at the vendor's Park Ridge facility. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis leveraging its small business status. Keytruda is a checkpoint inhibitor immunotherapy commonly used in oncology treatments, reflecting the government's ongoing pharmaceutical procurement needs for military healthcare systems.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables firm fixed-price orders for comprehensive pharmaceutical products supporting Department of Defense medical facilities worldwide. As a critical supplier in the federal pharmaceutical supply chain since its registration in SAM.gov in 2001, DMS Pharmaceutical Group has demonstrated substantial experience delivering branded and generic prescription drugs, biologics, and specialty medications to military healthcare operations. The company's positioning as a woman-owned small business has enabled it to successfully compete for multiple contract awards across diverse pharmaceutical product categories supporting the defense healthcare infrastructure.
Quick answers
Who was awarded contract SPE2DB25FDK70?
SPE2DB25FDK70 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 23, 2025.
How much is contract SPE2DB25FDK70 worth?
The government has obligated $98,275 on SPE2DB25FDK70.
Is contract SPE2DB25FDK70 an order under another contract?
Yes. SPE2DB25FDK70 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDK70 competed?
The extent of competition for SPE2DB25FDK70 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award